V Di Marzo Selected Research

CB1 Cannabinoid Receptor (CB1 Receptor)

1/2017	Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion.
6/2015	Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation.
4/2015	Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons.
7/2014	The endocannabinoid system--back to the scene of cardiometabolic risk factors control?
1/2014	Cannabinoids and schizophrenia: therapeutic prospects.
12/2013	Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
5/2013	The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
12/2012	The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity.
7/2008	Rimonabant in rats with a metabolic syndrome: good news after the depression.
7/2006	Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

V Di Marzo Research Topics

Disease

15	Inflammation (Inflammations) 11/2019 - 04/2000
12	Obesity 06/2016 - 04/2001
9	Pain (Aches) 01/2016 - 04/2000
7	Body Weight (Weight, Body) 04/2015 - 02/2003
5	Insulin Resistance 05/2013 - 07/2008
4	Multiple Sclerosis 12/2013 - 06/2000
4	Neoplasms (Cancer) 12/2001 - 01/2000
3	Chronic Pain 01/2016 - 11/2000
3	Glucose Intolerance 04/2015 - 02/2009
3	Schizophrenia (Dementia Praecox) 01/2014 - 10/2008
3	Type 2 Diabetes Mellitus (MODY) 05/2013 - 11/2007
3	Catalepsy 12/2000 - 10/2000
2	Visceral Pain 12/2017 - 05/2011
2	Dermatitis 01/2016 - 06/2010
2	Weight Loss (Weight Reduction) 07/2014 - 08/2008
2	Huntington Disease (Huntington's Disease) 10/2013 - 07/2001
2	Vomiting 08/2012 - 05/2007
2	Parkinson Disease (Parkinson's Disease) 08/2012 - 07/2000
2	Infections 03/2011 - 04/2009
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2008 - 05/2008
2	Feeding and Eating Disorders (Eating Disorder) 08/2007 - 04/2006
2	Hyperalgesia 03/2007 - 05/2000
2	Edema (Dropsy) 05/2003 - 11/2001
2	Breast Neoplasms (Breast Cancer) 08/2001 - 01/2000
2	Glioma (Gliomas) 04/2001 - 11/2000
2	Hypothermia 11/2000 - 10/2000
2	Prostatic Neoplasms (Prostate Cancer) 04/2000 - 01/2000
1	Ulcerative Colitis 11/2019
1	Mental Disorders (Mental Disorder) 01/2018
1	Dysbiosis 01/2018
1	Morbid Obesity 01/2017
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 01/2017
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2017
1	Abdominal Pain (Pain, Abdominal) 01/2017
1	Diabetic Neuropathies (Diabetic Neuropathy) 01/2016
1	Neuralgia (Stump Neuralgia) 08/2015
1	Constipation 06/2015
1	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2014
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2013

Drug/Important Bio-Agent (IBA)

38	EndocannabinoidsIBA 12/2017 - 01/2000
21	anandamide (arachidonylethanolamide)IBA 12/2017 - 01/2000
21	CannabinoidsIBA 07/2014 - 01/2000
13	palmidrolIBA 01/2017 - 04/2000
12	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2017 - 01/2000
10	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2011 - 01/2000
7	RimonabantIBA 07/2014 - 05/2001
4	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 10/2013 - 01/2000
4	Glucose (Dextrose)FDA LinkGeneric 05/2013 - 11/2007
4	Fatty Acids (Saturated Fatty Acids)IBA 11/2011 - 04/2000
4	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 04/2010 - 08/2001
3	Analgesics (Analgesic Drugs)IBA 01/2017 - 04/2000
3	Proteins (Proteins, Gene)FDA Link 08/2015 - 04/2001
3	EnzymesIBA 07/2014 - 08/2001
3	Pharmaceutical PreparationsIBA 07/2014 - 08/2008
3	CB2 Cannabinoid ReceptorIBA 10/2013 - 01/2000
3	Insulin (Novolin)FDA Link 05/2013 - 11/2007
3	Triglycerides (Triacylglycerol)IBA 05/2013 - 02/2009
3	Croton OilIBA 11/2008 - 10/2001
3	arvanilIBA 05/2007 - 10/2000
2	CytokinesIBA 11/2019 - 04/2000
2	2,4-dinitrofluorobenzene sulfonic acidIBA 11/2019 - 05/2013
2	Glycerol (Glycerine)FDA LinkGeneric 01/2017 - 11/2000
2	PlasticsIBA 01/2016 - 08/2015
2	Amino Acids FDA Link 08/2015 - 11/2001
2	Hormones (Hormone)IBA 11/2011 - 06/2001
2	Messenger RNA (mRNA)IBA 11/2011 - 03/2008
2	AmidesIBA 04/2011 - 11/2000
2	Therapeutic UsesIBA 06/2010 - 01/2010
2	arachidonoylserotoninIBA 04/2010 - 03/2007
2	Formaldehyde (Formol)FDA Link 11/2008 - 05/2000
2	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA 07/2006 - 06/2001
2	Cannabinoid Receptor AgonistsIBA 07/2006 - 10/2001
2	LigandsIBA 04/2004 - 01/2000
2	Ouabain (G Strophanthin)IBA 05/2003 - 11/2001
2	Nerve Growth Factor (NGF)IBA 04/2000 - 01/2000
1	cannabidivarinIBA 11/2019
1	dinitrobenzenesulfonic acidIBA 11/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	methylglyoxal bis(3-aminopropylamidinohydrazone)IBA 01/2018
1	oleoylethanolamideIBA 01/2017
1	polydatinIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	GhrelinIBA 01/2017
1	TRPV Cation ChannelsIBA 01/2016
1	adelmidrolIBA 01/2016
1	Streptozocin (Streptozotocin)FDA Link 01/2016
1	Glutamic Acid (Glutamate)FDA Link 08/2015
1	Neuropeptide YIBA 04/2015
1	Antipsychotic Agents (Antipsychotics)IBA 01/2014
1	malonic acid (malonate)IBA 10/2013
1	CholesterolIBA 05/2013
1	HDL LipoproteinsIBA 05/2013
1	LipidsIBA 05/2013
1	cannabichromeneIBA 05/2013
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2013
1	Peroxidase (Myeloperoxidase)IBA 05/2013
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2013

Therapy/Procedure

4	Analgesia 03/2007 - 10/2000
2	Therapeutics 08/2008 - 01/2007
1	Pain Management 01/2017